compound introduction
Apo CIII inhibits the activation of lipoprotein lipase by Apo CII. Reduced levels of Apo CIII result in higher fatty acid uptake from plasma triglycerides into adipose tissue. Thus, Apo CIII is a potential target for treatment of obesity and insulin resistance. The normal plasma concentration of Apo CIII is 8-15 mg per 100 ml. Prepared from fresh, non-frozen plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.
